Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Prevalence of Multiple Sclerosis in the Republic of Moldova.
Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Laquinimod in Relapsing-Remitting Multiple Sclerosis
Sema4A inhibits the therapeutic effect of IFN-β in EAE.
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Is the MS community ready to promote brain health? Reception and Symposium
Multiple Sclerosis: An Update.
Contribution of different relapse phenotypes to disability in multiple sclerosis.
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity.
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Multiple Sclerosis Society Education Conference
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
BRIEF: Teva files for Copaxone-Laquinimod patent
AB Science announces recruitment of first patient in phase 3 study of masitinib in progressive multiple sclerosis
UCSF Seminar: "MRI of Lesion Development and Repair in Multiple Sclerosis"
Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Pages